Daniel Teper
CEO, CYTOVIA ( Oncology), Founder and Board Direct
MMUNE Pharmaceuticals
COVA16 LLC?
France
Biography
Founder and CEO of IMMUNE Pharmaceuticals, Grew into a NASDAQ listed company in 3 years. IMMUNE focuses on Antibody Therapeutics with a lead phase II first in class mAb, bertilimumab, for the treatment of inflammatory diseases, including Crohn's and Colitis and Bullous Pemphigoid, an auto-immune orphan disease of the skin.
Research Interest
Founder and CEO of IMMUNE Pharmaceuticals, Grew into a NASDAQ listed company in 3 years. IMMUNE focuses on Antibody Therapeutics with a lead phase II first in class mAb, bertilimumab, for the treatment of inflammatory diseases, including Crohn's and Colitis and Bullous Pemphigoid, an auto-immune orphan disease of the skin.
